

COMPANY UPDATE

Riverstone Holdings (RSTON SP)

Semiconductor Industry Recovery Will Benefit Cleanroom Glove Segment

Riverstone's cleanroom gloves, which contribute about 80% of earnings, are expected to see a recovery in demand, driven by new clients onboarded in the preceding year and improvement in the semiconductor industry in 2024. On the healthcare gloves front, sustained product customisation efforts with new production lines are yielding results, as seen from increased demand for higher-margin customised healthcare gloves. We upgrade Riverstone to BUY with a 22% higher target price of S\$0.82.

WHAT'S NEW

- Demand for cleanroom gloves likely to improve on semiconductor recovery.** As Riverstone's customers are major manufacturers in the semiconductor and hard disk drive industries, the slowdown in the electronics and semiconductor sectors have led to softer cleanroom glove demand from 2022. Despite the challenging semiconductor market conditions in 2023, according to International Data Corporation (IDC), the semiconductor sales market is expected to recover with a 20% growth rate in 2024. This is also supported by the SEMI World Fab Forecast reporting 42 new projects in 2024, up from 11 in 2023. Management therefore expects demand for cleanroom gloves to recover in 2024. While management has shared that ASPs will be lowered to pass on cost savings from raw materials, they have also announced successful client acquisitions from the pharmaceutical sector. The impact of lower ASPs will likely be offset by higher volumes from both Riverstone's semiconductor customers and new clients, pointing to top-line growth for the cleanroom glove segment in 2024.
- Recent 3Q23 results signal potential turnaround in 2024.** Riverstone Holdings (Riverstone) reported a 3Q23 net profit of RM59.3m (+26.5% qoq, -6.6% yoy), with 9M23 net profit falling 43.9% yoy to RM152.9m. While the glove industry faced a slowdown from pandemic-induced oversupply and less-than-optimal utilisation in 2023, we note that 3Q23 gross profit margin improved 6ppt qoq and 1.1ppt yoy. This significant expansion was driven by a stronger product mix, with more customised healthcare gloves delivered, and lower raw material costs during the period.
- 97% dividend payout ratio as of 9M23 show a strong vote of confidence; strong balance sheet enables higher payout ratio above 100%, translating into an attractive dividend yield of 8.5% for 2024.** Riverstone declared an interim dividend of 5.0 sen, taking total 9M23 dividends to 10.0 sen/share (9M22: 16.0 sen/share), implying a 97% dividend payout ratio. Given that Riverstone has a strong balance sheet with net cash balance of RM951m as of 9M23, which is equivalent to S\$0.18/share (around 30% of market cap), a payout ratio above 100% is highly likely.

KEY FINANCIALS

Year to 31 Dec (RMm)	2021	2022	2023F	2024F	2025F
Net turnover	3,082	1,260	964	1,037	1,112
EBITDA	1,915	480	370	417	463
Operating profit	1,859	417	280	326	371
Net profit (rep./fact.)	1,418	314	212	246	267
Net profit (adj.)	1,418	314	212	246	267
EPS (sen)	95.7	21.2	14.3	16.6	18.0
PE (x)	2.5	11.2	16.6	14.3	13.1
P/B (x)	1.5	1.9	2.0	2.0	2.0
EV/EBITDA (x)	1.3	5.3	6.9	6.1	5.5
Dividend yield (%)	16.1	7.6	7.8	8.5	9.0
Net margin (%)	46.0	25.0	22.0	23.7	24.1
Net debt/(cash) to equity (%)	(69.1)	(57.5)	(55.8)	(54.3)	(52.6)
Interest cover (x)	12,763.5	20,865.5	3,697.4	4,167.9	n.a.
ROE (%)	76.8	15.0	11.6	13.8	15.2
Consensus net profit	-	-	216	266	302
UOBKH/Consensus (x)	-	-	0.98	0.93	0.89

Source: Riverstone, Bloomberg, UOB Kay Hian

BUY

(Upgraded)

Share Price	S\$0.67
Target Price	S\$0.82
Upside	+22.4%
(Previous TP)	S\$0.67

COMPANY DESCRIPTION

Riverstone Holdings produces, sells and distributes cleanroom products for use in highly-controlled and critical environments. Products include nitrite and natural rubber gloves, cleanroom packaging materials and finger cots, as well as face masks, face pouches, hoods, caps, jumpsuits and swabs.

STOCK DATA

GICS sector	Health Care
Bloomberg ticker:	RSTON SP
Shares issued (m):	1,482.2
Market cap (S\$m):	993.1
Market cap (US\$m):	741.2
3-mth avg daily t'over (US\$m):	0.9


Price Performance (%)

52-week high/low	S\$0.730/S\$0.520				
1mth	3mth	6mth	1yr	YTD	
(5.0)	15.5	8.1	7.4	(5.0)	

Major Shareholders

	%
Wong Teek Son	51.3
Lee Wai Keong	8.8
FY24 NAV/Share (RM)	1.20
FY24 Net Cash/Share (RM)	0.65

PRICE CHART



Source: Bloomberg

ANALYST(S)

Llleythan Tan
yirong@uobkayhian.com
+65 6590 6624

John Cheong
johncheong@uobkayhian.com
+65 6590 6623

- Benefitting from higher-margin customised healthcare gloves.** Besides being the leading global supplier for cleanroom and healthcare gloves, Riverstone offers products such as finger cots, cleanroom packaging bags and face masks. With more than 30 years of expertise, Riverstone's cleanroom products under own brand RS have a unique competitive advantage. As for its healthcare gloves, Riverstone is in the midst of demolishing its 10-year-old production lines to build newer lines for customised products. This has allowed it to expand its gross margin substantially, as customised gloves fetch approximately 30% gross profit margin, around six times that of generic gloves. Moving forward, increased demand for customised healthcare gloves will drive higher margins for Riverstone.

STOCK IMPACT

- Newer production lines by 2Q24 allow for better inventory management and higher margins.** To recap, Riverstone has six manufacturing facilities across Malaysia, Thailand and China with a total annual production capacity of 10.5b gloves. Previously, the company had planned to add more production lines to increase capacity by 1.5b gloves to 12b gloves by 1H23. However, with oversupply in the industry and overall utilisation rate averaging 60% in 2023, Riverstone has put a pause on the expansion plans. Instead, old production lines for generic gloves are being replaced with newer lines that can produce customised glove offerings. The new production lines are expected to be completed by 2Q24, and will give Riverstone the flexibility to better manage inventory requirements and effectively capture further demand for higher-margin customised gloves.

EARNINGS REVISION/RISK

- We have updated our 2023-24 forecasts** after accounting for lower cleanroom glove ASPs and sales volumes assumptions and add 2025 forecasts. Our 2023-25 revenue estimates are RM964.0m, RM1,037.2m and RM1,111.6m respectively, while 2023-25 PATMI estimates are RM212.0m, RM246.3m and RM267.4m respectively.
- ASPs for cleanroom gloves were around US\$92/'000 pcs, and we expect it to decline in 2023-2025 to US\$91/'000 pcs, US\$90/'000 pcs and US\$90/'000 pcs respectively.

VALUATION/RECOMMENDATION

- Upgrade to BUY with a 22% higher target price of S\$0.82**, pegged to 17.3x 2024F PE, or 1SD above the five-year historical mean. This is up from -1SD previously, to capture better earnings recovery in the glove industry. We have also rolled over our valuations to 2024. While glove companies continue to face underutilisation, we believe that Riverstone may outperform its peers with its higher-margin customised glove offerings.

SHARE PRICE CATALYST

- Higher-than-expected demand for cleanroom and healthcare gloves.
- Higher dividend payouts.

HISTORICAL PE BAND



Source: Bloomberg, UOB Kay Hian

PROFIT & LOSS

Year to 31 Dec (RMm)	2022	2023F	2024F	2025F
Net turnover	1,259.5	964.0	1,037.2	1,111.6
EBITDA	479.9	369.7	416.8	462.7
Deprec. & amort.	62.9	89.5	90.5	91.3
EBIT	417.0	280.2	326.3	371.4
Net interest income/(expense)	(0.0)	(0.1)	(0.1)	0.0
Pre-tax profit	417.0	280.1	326.2	371.4
Tax	(102.6)	(68.1)	(79.9)	(104.0)
Minorities	0.0	0.0	0.0	0.0
Net profit	314.4	212.0	246.3	267.4
Net profit (adj.)	314.4	212.0	246.3	267.4

BALANCE SHEET

Year to 31 Dec (RMm)	2022	2023F	2024F	2025F
Fixed assets	741.6	752.0	761.6	770.2
Other LT assets	1.2	1.2	1.2	1.2
Cash/ST investment	1,066.1	1,005.8	964.0	916.8
Other current assets	210.9	204.7	205.3	235.1
Total assets	2,019.8	1,963.8	1,932.1	1,923.4
ST debt	0.0	1.0	1.0	0.0
Other current liabilities	106.1	103.4	97.1	120.0
LT debt	0.0	1.0	1.0	0.0
Other LT liabilities	60.7	60.7	60.7	60.7
Shareholders' equity	1,852.9	1,797.7	1,772.3	1,742.7
Minority interest	0.0	0.0	0.0	0.0
Total liabilities & equity	2,019.8	1,963.8	1,932.1	1,923.4

CASH FLOW

Year to 31 Dec (RMm)	2022	2023F	2024F	2025F
Operating	381.8	305.1	329.9	351.8
Pre-tax profit	417.0	280.1	326.2	371.4
Tax	(102.6)	(68.1)	(79.9)	(104.0)
Deprec. & amort.	62.9	89.5	90.5	91.3
Associates	0.0	0.0	0.0	0.0
Working capital changes	130.1	3.5	(6.9)	(6.9)
Non-cash items	(0.0)	0.0	0.0	0.0
Other operating cashflows	(125.6)	0.0	0.0	0.0
Investing	(133.2)	(100.0)	(100.0)	(100.0)
Capex (growth)	(133.4)	(100.0)	(100.0)	(100.0)
Proceeds from sale of assets	0.3	0.0	0.0	0.0
Others	0.0	0.0	0.0	0.0
Financing	(801.9)	(265.3)	(271.7)	(299.0)
Dividend payments	(800.4)	(267.3)	(271.7)	(297.0)
Issue of shares	0.0	0.0	0.0	0.0
Proceeds from borrowings	0.0	2.0	0.0	0.0
Loan repayment	(1.6)	0.0	0.0	(2.0)
Others/interest paid	0.0	0.0	0.0	0.0
Net cash inflow (outflow)	(553.3)	(60.2)	(41.9)	(47.1)
Beginning cash & cash equivalent	1,612.9	1,066.1	1,005.8	964.0
Changes due to forex impact	6.5	0.0	0.0	0.0
Ending cash & cash equivalent	1,066.1	1,005.8	964.0	916.8

KEY METRICS

Year to 31 Dec (%)	2022	2023F	2024F	2025F
Profitability				
EBITDA margin	38.1	38.4	40.2	41.6
Pre-tax margin	33.1	29.1	31.5	33.4
Net margin	25.0	22.0	23.7	24.1
ROA	13.3	10.6	12.6	13.9
ROE	15.0	11.6	13.8	15.2
Growth				
Turnover	(59.1)	(23.5)	7.6	7.2
EBITDA	(74.9)	(23.0)	12.7	11.0
Pre-tax profit	(77.6)	(32.8)	16.5	13.8
Net profit	(77.8)	(32.6)	16.2	8.6
Net profit (adj.)	(77.8)	(32.6)	16.2	8.6
EPS	(77.9)	(32.6)	16.2	8.6
Leverage				
Debt to total capital	0.0	0.1	0.1	0.0
Debt to equity	0.0	0.1	0.1	0.0
Net debt/(cash) to equity	(57.5)	(55.8)	(54.3)	(52.6)
Interest cover (x)	20,865.5	3,697.4	4,167.9	n.a.

Disclosures/Disclaimers

This report is prepared by UOB Kay Hian Private Limited ("UOBKH"), which is a holder of a capital markets services licence and an exempt financial adviser in Singapore.

This report is provided for information only and is not an offer or a solicitation to deal in securities or to enter into any legal relations, nor an advice or a recommendation with respect to such securities.

This report is prepared for general circulation. It does not have regard to the specific investment objectives, financial situation and the particular needs of any recipient hereof. Advice should be sought from a financial adviser regarding the suitability of the investment product, taking into account the specific investment objectives, financial situation or particular needs of any person in receipt of the recommendation, before the person makes a commitment to purchase the investment product.

This report is confidential. This report may not be published, circulated, reproduced or distributed in whole or in part by any recipient of this report to any other person without the prior written consent of UOBKH. This report is not directed to or intended for distribution to or use by any person or any entity who is a citizen or resident of or located in any locality, state, country or any other jurisdiction as UOBKH may determine in its absolute discretion, where the distribution, publication, availability or use of this report would be contrary to applicable law or would subject UOBKH and its connected persons (as defined in the Financial Advisers Act, Chapter 110 of Singapore) to any registration, licensing or other requirements within such jurisdiction.

The information or views in the report ("Information") has been obtained or derived from sources believed by UOBKH to be reliable. However, UOBKH makes no representation as to the accuracy or completeness of such sources or the Information and UOBKH accepts no liability whatsoever for any loss or damage arising from the use of or reliance on the Information. UOBKH and its connected persons may have issued other reports expressing views different from the Information and all views expressed in all reports of UOBKH and its connected persons are subject to change without notice. UOBKH reserves the right to act upon or use the Information at any time, including before its publication herein.

Except as otherwise indicated below, (1) UOBKH, its connected persons and its officers, employees and representatives may, to the extent permitted by law, transact with, perform or provide broking, underwriting, corporate finance-related or other services for or solicit business from, the subject corporation(s) referred to in this report; (2) UOBKH, its connected persons and its officers, employees and representatives may also, to the extent permitted by law, transact with, perform or provide broking or other services for or solicit business from, other persons in respect of dealings in the securities referred to in this report or other investments related thereto; (3) the officers, employees and representatives of UOBKH may also serve on the board of directors or in trustee positions with the subject corporation(s) referred to in this report. (All of the foregoing is hereafter referred to as the "Subject Business"); and (4) UOBKH may otherwise have an interest (including a proprietary interest) in the subject corporation(s) referred to in this report.

As of the date of this report, no analyst responsible for any of the content in this report has any proprietary position or material interest in the securities of the corporation(s) which are referred to in the content they respectively author or are otherwise responsible for.

IMPORTANT DISCLOSURES FOR U.S. PERSONS

This research report was prepared by UOBKH, a company authorized, as noted above, to engage in securities activities in Singapore. UOBKH is not a registered broker-dealer in the United States and, therefore, is not subject to U.S. rules regarding the preparation of research reports and the independence of research analysts. This research report is provided for distribution by UOBKH (whether directly or through its US registered broker dealer affiliate named below) to "major U.S. institutional investors" in reliance on the exemption from registration provided by Rule 15a-6 of the U.S. Securities Exchange Act of 1934, as amended (the "Exchange Act"). All US persons that receive this document by way of distribution from or which they regard as being from UOBKH by their acceptance thereof represent and agree that they are a major institutional investor and understand the risks involved in executing transactions in securities.

Any U.S. recipient of this research report wishing to effect any transaction to buy or sell securities or related financial instruments based on the information provided in this research report should do so only through UOB Kay Hian (U.S.) Inc ("UOBKHUS"), a registered broker-dealer in the United States. Under no circumstances should any recipient of this research report effect any transaction to buy or sell securities or related financial instruments through UOBKH.

UOBKHUS accepts responsibility for the contents of this research report, subject to the terms set out below, to the extent that it is delivered to and intended to be received by a U.S. person other than a major U.S. institutional investor.

The analyst whose name appears in this research report is not registered or qualified as a research analyst with the Financial Industry Regulatory Authority ("FINRA") and may not be an associated person of UOBKHUS and, therefore, may not be subject to applicable restrictions under FINRA Rules on communications with a subject company, public appearances and trading securities held by a research analyst account.

Analyst Certification/Regulation AC

Each research analyst of UOBKH who produced this report hereby certifies that (1) the views expressed in this report accurately reflect his/her personal views about all of the subject corporation(s) and securities in this report; (2) the report was produced independently by him/her; (3) he/she does not carry out, whether for himself/herself or on behalf of UOBKH or any other person, any of the Subject Business involving any of the subject corporation(s) or securities referred to in this report; and (4) he/she has not received and will not receive any compensation that is directly or indirectly related or linked to the recommendations or views expressed in this report or to any sales, trading, dealing or corporate finance advisory services or transaction in respect of the securities in this report. However, the compensation received by each such research analyst is based upon various factors, including UOBKH's total revenues, a portion of which are generated from UOBKH's business of dealing in securities.

Reports are distributed in the respective countries by the respective entities and are subject to the additional restrictions listed in the following table.

General	This report is not intended for distribution, publication to or use by any person or entity who is a citizen or resident of or located in any country or jurisdiction where the distribution, publication or use of this report would be contrary to applicable law or regulation.
Hong Kong	This report is distributed in Hong Kong by UOB Kay Hian (Hong Kong) Limited ("UOBKHHK"), which is regulated by the Securities and Futures Commission of Hong Kong. Neither the analyst(s) preparing this report nor his associate, has trading and financial interest and relevant relationship specified under Para. 16.4 of Code of Conduct in the listed corporation covered in this report. UOBKHHK does not have financial interests and business relationship specified under Para. 16.5 of Code of Conduct with the listed corporation covered in this report. Where the report is distributed in Hong Kong and contains research analyses or reports from a foreign research house, please note: (i) recipients of the analyses or reports are to contact UOBKHHK (and not the relevant foreign research house) in Hong Kong in respect of any matters arising from, or in connection with, the analysis or report; and (ii) to the extent that the analyses or reports are delivered to and intended to be received by any person in Hong Kong who is not a professional investor, or institutional investor, UOBKHHK accepts legal responsibility for the contents of the analyses or reports only to the extent required by law.
Indonesia	This report is distributed in Indonesia by PT UOB Kay Hian Sekuritas, which is regulated by Financial Services Authority of Indonesia ("OJK"). Where the report is distributed in Indonesia and contains research analyses or reports from a foreign research house, please note recipients of the analyses or reports are to contact PT UOBKH (and not the relevant foreign research house) in Indonesia in respect of any matters arising from, or in connection with, the analysis or report.
Malaysia	Where the report is distributed in Malaysia and contains research analyses or reports from a foreign research house, the recipients of the analyses or reports are to contact UOBKHM (and not the relevant foreign research house) in Malaysia, at +603-21471988, in respect of any matters arising from, or in connection with, the analysis or report as UOBKHM is the registered person under CMSA to distribute any research analyses in Malaysia.
Singapore	This report is distributed in Singapore by UOB Kay Hian Private Limited ("UOBKH"), which is a holder of a capital markets services licence and an exempt financial adviser regulated by the Monetary Authority of Singapore. Where the report is distributed in Singapore and contains research analyses or reports from a foreign research house, please note: (i) recipients of the analyses or reports are to contact UOBKH (and not the relevant foreign research house) in Singapore in respect of any matters arising from, or in connection with, the analysis or report; and (ii) to the extent that the analyses or reports are delivered to and intended to be received by any person in Singapore who is not an accredited investor, expert investor or institutional investor, UOBKH accepts legal responsibility for the contents of the analyses or reports only to the extent required by law.
Thailand	This report is distributed in Thailand by UOB Kay Hian Securities (Thailand) Public Company Limited, which is regulated by the Securities and Exchange Commission of Thailand.
United Kingdom	This report is being distributed in the UK by UOB Kay Hian (U.K.) Limited, which is an authorised person in the meaning of the Financial Services and Markets Act and is regulated by The Financial Conduct Authority. Research distributed in the UK is intended only for institutional clients.
United States of America ('U.S.')	This report cannot be distributed into the U.S. or to any U.S. person or entity except in compliance with applicable U.S. laws and regulations. It is being distributed in the U.S. by UOB Kay Hian (US) Inc, which accepts responsibility for its contents. Any U.S. person or entity receiving this report and wishing to effect transactions in any securities referred to in the report should contact UOB Kay Hian (US) Inc. directly.

Copyright 2024, UOB Kay Hian Pte Ltd. All rights reserved.

<http://research.uobkayhian.com>

RCB Regn. No. 197000447W